Cam­bri­an's an­ti-ag­ing mis­sion ex­pands with new fi­brot­ic dis­ease biotech

Cam­bri­an Bio­Phar­ma has a new pipeline com­pa­ny fo­cused on a dis­ease tar­get that hasn’t met much suc­cess.

The new drug de­vel­op­er, called Is­ter­ian Biotech, emerged from stealth Thurs­day morn­ing, Cam­bri­an an­nounced. Georg Ter­stap­pen, Cam­bri­an’s EVP of drug dis­cov­ery, will be Is­ter­ian’s pres­i­dent and board chair.

Cam­bri­an CEO James Pey­er tells End­points News the biotech is fo­cused on de­vel­op­ing in­hibitor mol­e­cules for trans­g­lu­t­a­m­i­nase 2, al­so called TG2.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN